María Pilar
Garrido López
Profesor/a Asociado/a en CC. de la Salud
University of Chicago
Chicago, Estados UnidosPublications in collaboration with researchers from University of Chicago (2)
2024
2023
-
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Journal of Thoracic Oncology, Vol. 18, Núm. 2, pp. 181-193